Literature DB >> 24986877

Ibritumomab tiuxetan plus BEAM in refractory diffuse large B-cell lymphoma.

Vít Procházka1, Antonín Hluší2.   

Abstract

Entities:  

Keywords:  autologous transplantation; diffuse large B-cell lymphoma; ibritumomab tiuxetan; relapse

Mesh：

Year:  2014        PMID： 24986877      PMCID： PMC4077095          DOI： 10.3324/haematol.2014.107177

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  2 in total

1.  Autologous stem cell transplantation after conditioning with yttrium-90 ibritumomab tiuxetan plus BEAM in refractory non-Hodgkin diffuse large B-cell lymphoma: results of a prospective, multicenter, phase II clinical trial.

Authors:  Javier Briones; Silvana Novelli; José A García-Marco; José F Tomás; Teresa Bernal; Carlos Grande; Miguel A Canales; Antonio Torres; José M Moraleda; Carlos Panizo; Isidro Jarque; Francisca Palmero; Miguel Hernández; Eva González-Barca; Dulce López; Dolores Caballero
Journal:  Haematologica       Date:  2013-10-25       Impact factor: 9.941

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.